233 related articles for article (PubMed ID: 21350804)
21. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Ledermann JA; Hackshaw A; Kaye S; Jayson G; Gabra H; McNeish I; Earl H; Perren T; Gore M; Persic M; Adams M; James L; Temple G; Merger M; Rustin G
J Clin Oncol; 2011 Oct; 29(28):3798-804. PubMed ID: 21859991
[TBL] [Abstract][Full Text] [Related]
23. Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Awasthi N; Schwarz RE
Onco Targets Ther; 2015; 8():3691-701. PubMed ID: 26677336
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
Roth GJ; Heckel A; Colbatzky F; Handschuh S; Kley J; Lehmann-Lintz T; Lotz R; Tontsch-Grunt U; Walter R; Hilberg F
J Med Chem; 2009 Jul; 52(14):4466-80. PubMed ID: 19522465
[TBL] [Abstract][Full Text] [Related]
25. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic and anti-HER therapy.
Gasparini G; Sarmiento R; Longo R
Biomed Pharmacother; 2006 Jul; 60(6):263-5. PubMed ID: 16815667
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
29. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
30. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
31. Targeting angiogenesis in the treatment of lung cancer.
Wheatley-Price P; Shepherd FA
J Thorac Oncol; 2008 Oct; 3(10):1173-84. PubMed ID: 18827616
[TBL] [Abstract][Full Text] [Related]
32. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
33. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
34. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
36. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
Byers LA; Heymach JV
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
38. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
Reck M; Kaiser R; Eschbach C; Stefanic M; Love J; Gatzemeier U; Stopfer P; von Pawel J
Ann Oncol; 2011 Jun; 22(6):1374-1381. PubMed ID: 21212157
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
40. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
Bennis Y; Guillet B; Curti C; Pisano P
Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
